NCT02064582View on ClinicalTrials.gov

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

June 9, 2018

Study Completion Date

June 9, 2018

Conditions
Prostate Cancer
Interventions
DRUG

Enzalutamide

160mg by mouth each day

DRUG

Leuprolide acetate

22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months

RADIATION

radiation

External beam radiation will be delivered as per standard radiation therapy protocol

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT02064582 - Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer | Biotech Hunter | Biotech Hunter